The Medical Letter on Drugs and Therapeutics
Tobramycin Inhalation Powder (Tobi Podhaler) for Cystic Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Inhaled antibiotics, which can achieve high concentrations in the lung with minimal systemic side effects, are probably the most effective therapy available for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.1 An orally inhaled dry powder formulation of the aminoglycoside antibiotic tobramycin (Tobi Podhaler – Novartis) has been approved by the FDA for management of P. aeruginosa pulmonary infection in cystic fibrosis patients ≥6 years old. The new formulation is administered via a hand-held pocket-sized inhaler. Tobramycin is also available as an inhalation solution (Tobi) for administration via a nebulizer. An inhalation solution of aztreonam (Cayston), administered via a nebulizer, is also approved for this indication.2

CLINICAL STUDIES — A randomized, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tobramycin Inhalation Powder (Tobi Podhaler) for Cystic Fibrosis
Article code: 1419c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian